CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 117 enrolled
Drug / intervention
Human insulin 30/70 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00420095
NCT00420095Phase 4Completed
CompareCT.gov

Comparison of HbA1c in Type 1 or Type 2 Diabetic Patients Using Insulin Treated Twice Daily With Either Insulin Lispro Low Mixture or Human Insulin Mix 30/70

Eli Lilly and Company·interventional·Posted Jan 9, 2007·Updated Jun 17, 2009

In Brief

A Phase 4 clinical trial evaluating Human insulin 30/70 and Insulin lispro low mix for Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2. Completed, enrolled 117 participants across 4 sites.

Detailed Summary

The purpose of this study is to compare glycemic control (HbA1c) in Chinese patients with type 1 or type 2 diabetes when treated with insulin lispro low mixture and human insulin 30/70.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 9, 2007
Enrollment StartJan 1, 2007
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 19.5 years ago

Interventions

Human insulin 30/70drug

Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks

Insulin lispro low mixdrug

Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks